Literature DB >> 30544475

Anti-TIF1γ antibody predicted malignancy of thymic tumor with dermatomyositis as an "autoimmune tumor marker": A case report.

Kohei Karino1, Yuichiro Fujieda, Takuya Kawamura, Nobuya Abe, Shuhei Shimoyama, Michihito Kono, Masaru Kato, Shinsuke Yasuda, Tatsuya Atsumi.   

Abstract

RATIONALE: An association between inflammatory myopathy and malignancy has been recognized particularly in patients positive for anti-transcription intermediary factor 1γ (TIF1γ) antibody. We report a case of anti-TIF1γ antibody positive dermatomyositis (DM) associated with thymic carcinoma which radiographically mimicked benign tumor. PATIENT CONCERNS: A 72-year-old man presented typical characteristic cutaneous manifestations and proximal muscle weakness with elevated levels of myogenic enzymes. An anterior mediastinal tumor was detected by computed tomography (CT) scan and radiographically assessed to be benign with distinct borders and little enhancement. DIAGNOSES: DM with anti-TIF1γ antibody and thymic carcinoma.
INTERVENTIONS: Thymic carcinoma was completely resected by surgery. DM was induced into remission with glucocorticoid treatment. OUTCOMES: The serum level of myogenic enzyme remained within normal range under low-dose glucocorticoid maintenance. No evidence of carcinoma recurrence with CT scan was observed at 1-year follow up. LESSONS: The present case indicated that anti-TIF1γ antibody would play a role as the "autoimmune tumor marker" in patients with inflammatory myopathy.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30544475      PMCID: PMC6310527          DOI: 10.1097/MD.0000000000013563

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.817


Introduction

Dermatomyositis (DM) is an idiopathic inflammatory myopathy, characterized by proximal skeletal muscle weakness, and specific cutaneous manifestations. High prevalence of malignant diseases in patients with inflammatory myopathy has been well recognized.[ DM is diagnosed based on the classification criteria of Bohan and Peter. It includes clinical examinations such as myogenic enzymes, electromyography, and muscle biopsy in addition to clinical manifestations.[ Recently a number of myositis-specific autoantibodies related with clinical characteristics of DM have been reported.[ Among them, anti-transcription intermediary factor 1γ (TIF1γ) antibody is more prevalent in DM patients with malignancy than those without.[ Thymic tumors including thymoma and thymic carcinoma are diagnosed by histology. Thymic carcinomas show cytologic atypia, invasive margins, and loss of an organotypic appearance. [ We report a case of anti-TIF1γ antibody positive DM associated with thymic carcinoma which radiographically mimicked a benign tumor.

Case report

A 72-year-old Japanese man presented with painful skin rashes on knuckles and eyelids. His medical history was notable for a 15-year history of diabetes mellitus and a stroke 5 years ago. His family history was unremarkable. Three months after his first visit, an elevated serum level of creatine kinase (CK) was detected in outpatient clinic and he was admitted to a nearby hospital. On physical examination, the following were noted: proximal muscle weakness, heliotrope rash of the eyelids, erythematous rashes on elbows, shoulders, and right thigh, and Gottron's sign over his knuckles (Fig. 1). Laboratory tests showed elevated serum levels of CK (1576 IU/L) and aldolase (8.2 U/L), and the antinuclear antibody was positive (1:1280, speckled and nucleolar pattern). He was diagnosed with DM and was referred to our hospital for further investigation and treatment. While autoantibodies including anti-aminoacyl tRNA synthetase antibody, anti-Mi-2 antibody, and anti-melanoma differentiation-associated gene 5 antibodies were negative, anti-TIF1γ antibody was positive (107 indexes). Magnetic resonance images showed high-intensity areas on whole-body muscles with short-tau inversion recovery images, suggesting the presence of muscular inflammation. A skin biopsy specimen revealed mononuclear cell infiltrations around vessels at the dermal-epidermal interface. The result of electromyogram of the proximal muscles was compatible with inflammatory myopathy.
Figure 1

Cutaneous manifestations of patient. (A) Heliotrope rash over the upper eyelids. (B) Gottron's papules overlying knuckles. (C) Erythematous rash on shoulders.

Cutaneous manifestations of patient. (A) Heliotrope rash over the upper eyelids. (B) Gottron's papules overlying knuckles. (C) Erythematous rash on shoulders. Computed tomography (CT) scans showed an anterior mediastinal mass with diameter of 23 mm. It had homogenous density with little contrast effect and well-defined borders (Fig. 2), leading to the radiographic diagnosis as non-invasive thymoma or thymic cyst. Knowing that anti-TIF1γ antibody has been related to malignancies in DM patients, we performed thoracoscopic thymectomy to further confirm the diagnosis. Based on the histologic findings, this tumor was ultimately diagnosed as squamous cell carcinoma of the thymus. Two weeks after the surgery, oral glucocorticoid (1.0 mg/kg/day) was administered followed by immediate disappearance of his skin involvement and by gradual improvement in muscle weakness. Under low-dose glucocorticoid maintenance, there is no feature of disease relapse at least for 1 year.
Figure 2

Chest computed tomography scans showed a mass in anterior mediastinum (arrows) (A; plain, B; enhanced). It had well-defined borders with little contrast effect.

Chest computed tomography scans showed a mass in anterior mediastinum (arrows) (A; plain, B; enhanced). It had well-defined borders with little contrast effect.

Discussion

The prevalence of malignancy in patients with DM has been estimated approximately 30%. [ A type and site of cancers occurring in DM patients are mostly comparable in the general population. [ Although DM are usually treated with combination of glucocorticoid and immunosuppressive agents, some cases of paraneoplastic DM achieved remission without such treatment after the cure of underlying malignancy.[ In our case, however, immunosuppressive treatment was needed, indicating that paraneoplastic immune response had been established and did not need sustained antigen presentation from cancer cells. Anti-TIF1γ antibody is identified in about 20% of adult DM patients.[ Among them, 60% to 80% have malignant diseases. [ Despite such strong correlation between anti-TIF1γ antibody, malignancy, and myositis, the pathogenesis of the interaction between them remains unclear. TIF1γ has been known as a tumor suppressor by preventing TGF-β pathway, [ while overexpression of TIF1γ has been reported to be associated with oncogenesis and poor prognosis in some cancers.[ It has been hypothesized that mutations of TIF1γ genes in tumors provoke a specific anti-tumoral immune response which secondarily causes a cross-reactivity to the target organs of myositis, including muscle, and skin.[ The occurrence of thymic carcinoma is extremely rare in DM[ and, vice versa, the incidence of paraneoplastic syndrome with thymic carcinoma is very low.[ The prognosis of thymic carcinoma is, however, obviously poorer compared with that of thymoma. Surgery should be considered in the management of thymic carcinoma. Complete resection is extremely important, and delay of diagnosis would result in poor outcome.[ In addition, the diagnostic accuracy of radiography for thymic tumors is advanced but still has limitation to some extent.[ In our case combined assessment using anti-TIF1γ antibody and conventional screening for malignancy, although the latter had failed to present malignant aspect, ultimately lead to curative treatment. Anti-TIF1γ antibody played a role as “autoimmune tumor marker” in the management of our patient.

Author contributions

Conceptualization: Yuichiro Fujieda. Supervision: Yuichiro Fujieda, Tatsuya Atsumi. Writing – original draft: Kohei Karino. Writing – review & editing: Yuichiro Fujieda, Takuya Kawamura, Nobuya Abe, Shuhei Shimoyama, Michihito Kono, Masaru Kato, Shinsuke Yasuda, Tatsuya Atsumi.
  23 in total

Review 1.  Polymyositis and dermatomyositis (second of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-20       Impact factor: 91.245

2.  Incidence and predictive factors for malignancies in 136 Japanese patients with dermatomyositis, polymyositis and clinically amyopathic dermatomyositis.

Authors:  Kohei Azuma; Hidehiro Yamada; Michiko Ohkubo; Yoshioki Yamasaki; Masaomi Yamasaki; Machiko Mizushima; Shoichi Ozaki
Journal:  Mod Rheumatol       Date:  2010-10-05       Impact factor: 3.023

3.  Expression of the dermatomyositis autoantigen transcription intermediary factor 1γ in regenerating muscle.

Authors:  Payam Mohassel; Paul Rosen; Livia Casciola-Rosen; Katherine Pak; Andrew L Mammen
Journal:  Arthritis Rheumatol       Date:  2015-01       Impact factor: 10.995

Review 4.  Idiopathic Inflammatory Myopathies and Malignancy: a Comprehensive Review.

Authors:  Eleni Tiniakou; Andrew L Mammen
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

5.  Association of overexpression of TIF1γ with colorectal carcinogenesis and advanced colorectal adenocarcinoma.

Authors:  Shilpa Jain; Shashideep Singhal; Franto Francis; Cristina Hajdu; Jin-Hua Wang; Arief Suriawinata; Yin-Quan Wang; Miao Zhang; Elizabeth H Weinshel; Fritz Francois; Zhi-Heng Pei; Peng Lee; Ru-Liang Xu
Journal:  World J Gastroenterol       Date:  2011-09-21       Impact factor: 5.742

6.  Clinical and functional significance of WHO classification on human thymic epithelial neoplasms: a study of 146 consecutive tumors.

Authors:  M Okumura; S Miyoshi; Y Fujii; Y Takeuchi; H Shiono; M Inoue; K Fukuhara; Y Kadota; H Tateyama; T Eimoto; H Matsuda
Journal:  Am J Surg Pathol       Date:  2001-01       Impact factor: 6.394

7.  Paraneoplastic dermatomyositis as presentation of thymic carcinoma.

Authors:  Andrea Dell'Amore; Nizar Asadi; Guido Caroli; Giampiero Dolci; Alessandro Bini; Franco Stella
Journal:  Gen Thorac Cardiovasc Surg       Date:  2012-08-21

8.  Anti-TIF1-γ antibody and cancer-associated myositis: A clinicohistopathologic study.

Authors:  Ayumi Hida; Takenari Yamashita; Yuji Hosono; Manami Inoue; Kenichi Kaida; Masato Kadoya; Yusuke Miwa; Nobuyuki Yajima; Reika Maezawa; Satoko Arai; Kazuhiro Kurasawa; Kazuhiro Ito; Hiroyuki Shimada; Tomoko Iwanami; Masahiro Sonoo; Yuki Hatanaka; Shigeo Murayama; Ayumi Uchibori; Atsuro Chiba; Hitoshi Aizawa; Takayuki Momoo; Yoshiharu Nakae; Yasuhisa Sakurai; Yasushi Shiio; Hideji Hashida; Toshihiro Yoshizawa; Yoshio Sakiyama; Aya Oda; Kiyoharu Inoue; Sousuke Takeuchi; Nobue K Iwata; Hidetoshi Date; Naoki Masuda; Takashi Mikata; Yasufumi Motoyoshi; Yoshikazu Uesaka; Meiko Hashimoto Maeda; Ran Nakashima; Shoji Tsuji; Shin Kwak; Tsuneyo Mimori; Jun Shimizu
Journal:  Neurology       Date:  2016-06-24       Impact factor: 9.910

9.  TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients.

Authors:  Loay Kassem; Mathieu Deygas; Laurent Fattet; Jonathan Lopez; Thibaut Goulvent; Emilie Lavergne; Sylvie Chabaud; Nicolas Carrabin; Nicolas Chopin; Thomas Bachelot; Germain Gillet; Isabelle Treilleux; Ruth Rimokh
Journal:  BMC Cancer       Date:  2015-06-04       Impact factor: 4.430

10.  Evidence supports blind screening for internal malignancy in dermatomyositis: Data from 2 large US dermatology cohorts.

Authors:  Hayley Leatham; Courtney Schadt; Sarah Chisolm; Deborah Fretwell; Lorinda Chung; Jeffrey P Callen; David Fiorentino
Journal:  Medicine (Baltimore)       Date:  2018-01       Impact factor: 1.889

View more
  1 in total

Review 1.  Anti-transcription intermediary factor 1 gamma (TIF1γ) antibody-positive dermatomyositis associated with ascending colon cancer: a case report and review of the literature.

Authors:  Ryohei Ono; Tomohiro Kumagae; Mari Igasaki; Takaaki Murata; Masaki Yoshizawa; Izumi Kitagawa
Journal:  J Med Case Rep       Date:  2021-03-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.